In yesterday’s Wall Street session, Geron Corporation (NASDAQ:GERN) shares traded at $3.21, up 4.22% from the previous session.
As of this writing, 6 analysts cover Geron Corporation (NASDAQ:GERN). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $4.00, we find $5.00. Given the previous closing price of $3.08, this indicates a potential upside of 62.34 percent. GERN stock price is now 6.45% away from the 50-day moving average and 22.03% away from the 200-day moving average. The market capitalization of the company currently stands at $1.65B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
There are 1 analysts who have given it a hold rating, whereas 4 have given it a buy rating. Brokers who have rated the stock have averaged $4.83 as their price target over the next twelve months.
With the price target of $3, Goldman recently initiated with Neutral rating for Geron Corporation (NASDAQ: GERN).
In other news, LAWLIS V BRYAN, Director sold 35,000 shares of the company’s stock on May 11. The stock was sold for $105,000 at an average price of $3.00. Upon completion of the transaction, the Director now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On May 01, Director Molineaux Susan sold 35,000 shares of the business’s stock. A total of $86,800 was realized by selling the stock at an average price of $2.48. Insiders disposed of 2,194,719 shares of company stock worth roughly $7.05 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GERN stock. A new stake in Geron Corporation shares was purchased by FAIRMOUNT FUNDS MANAGEMENT LLC during the first quarter worth $22,805,000. ARTAL GROUP S.A. invested $17,867,000 in shares of GERN during the first quarter. In the first quarter, BAKER BROS. ADVISORS LP acquired a new stake in Geron Corporation valued at approximately $9,827,000. POINT72 ASSET MANAGEMENT, L.P. acquired a new stake in GERN for approximately $9,608,000. OCTAGON CAPITAL ADVISORS LP purchased a new stake in GERN valued at around $7,312,000 in the second quarter. In total, there are 242 active investors with 50.50% ownership of the company’s stock.
Friday morning saw Geron Corporation (NASDAQ: GERN) opened at $3.1400. During the past 12 months, Geron Corporation has had a low of $1.48 and a high of $3.84. As of last week, the company has a debt-to-equity ratio of 0.16, a current ratio of 8.80, and a quick ratio of 8.80. The fifty day moving average price for GERN is $3.0298 and a two-hundred day moving average price translates $2.6318 for the stock.
The latest earnings results from Geron Corporation (NASDAQ: GERN) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.07, beating analysts’ expectations of -$0.1 by 0.03. This compares to -$0.09 EPS in the same period last year. The company reported revenue of $21000.0 for the quarter, compared to $0.12 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -82.93 percent. For the current quarter, analysts expect GERN to generate $70k in revenue.
Geron Corporation(GERN) Company Profile
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
